Get the Stockscreener App
14.93
0.20%
0.03
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Axogen Inc stock is traded at $14.93, with a volume of 1.51M.
It is up +0.20% in the last 24 hours and up +27.93% over the past month.
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.
See More
Previous Close:
$14.90
Open:
$15
24h Volume:
1.51M
Relative Volume:
1.39
Market Cap:
$686.97M
Revenue:
$159.01M
Net Income/Loss:
$-21.72M
P/E Ratio:
-28.71
EPS:
-0.52
Net Cash Flow:
$-20.63M
1W Performance:
+7.41%
1M Performance:
+27.93%
6M Performance:
-17.65%
1Y Performance:
+35.48%
1-Day Range:
$14.72
$15.11
1-Week Range:
$13.75
$15.11
52-Week Range:
$9.215
$21.00
Axogen Inc Stock (AXGN) Company Profile
Name
Axogen Inc
Sector
Industry
Phone
(386) 462-6817
Address
13631 PROGRESS BLVD., ALACHUA, FL
Compare AXGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AXGN
Axogen Inc
|
14.93 | 685.59M | 159.01M | -21.72M | -20.63M | -0.52 |
|
ABT
Abbott Laboratories
|
131.75 | 225.01B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.17 | 154.32B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
381.91 | 144.71B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
93.02 | 117.85B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.26 | 45.90B | 5.69B | 1.41B | 577.90M | 6.95 |
Axogen Inc Stock (AXGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-25 | Initiated | Lake Street | Buy |
| Jul-01-24 | Initiated | Raymond James | Outperform |
| Nov-11-22 | Resumed | Jefferies | Buy |
| May-09-22 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-11-22 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-23-20 | Initiated | Guggenheim | Buy |
| Jun-16-20 | Resumed | Cantor Fitzgerald | Overweight |
| May-07-20 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-02-20 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-07-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-12-19 | Initiated | Canaccord Genuity | Buy |
| Mar-02-18 | Reiterated | Lake Street | Buy |
| Jan-05-18 | Resumed | Cantor Fitzgerald | Overweight |
| Nov-30-17 | Initiated | Jefferies | Buy |
| Nov-21-17 | Reiterated | Lake Street | Buy |
| Jul-31-17 | Initiated | Leerink Partners | Outperform |
| Jun-30-17 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-06-17 | Initiated | ROTH Capital | Buy |
| Nov-22-16 | Upgrade | Lake Street | Hold → Buy |
| Nov-07-16 | Reiterated | Wedbush | Outperform |
| Nov-03-16 | Downgrade | Lake Street | Buy → Hold |
| Aug-04-16 | Reiterated | Wedbush | Outperform |
| May-14-14 | Initiated | Dawson James | Buy |
| Oct-31-13 | Reiterated | Ladenburg Thalmann | Buy |
View All
Axogen Inc Stock (AXGN) Latest News
Raymond James Slashes PT on Axogen (AXGN) to $20 From $21 - MSN
Wall Street Analysts Predict a 76.37% Upside in AxoGen (AXGN): Here's What You Should Know - MSN
Will Axogen Inc. outperform its industry peersTrade Risk Assessment & Weekly Breakout Stock Alerts - newsyoung.net
AxoGen’s SWOT analysis: nerve repair innovator’s stock poised for growth By Investing.com - Investing.com Nigeria
AxoGen’s SWOT analysis: nerve repair innovator’s stock poised for growth - Investing.com India
AxoGen price target lowered to $20 from $21 at Raymond James - MSN
Axogen's Strategic Position in the Evolving Peripheral Nerve Repair Market: A Deep Dive into Clinical Success, Regulatory Momentum, and Growth Potential - AInvest
Axogen: Broad Range Of Outcomes Still Present, Opting To Remain Sidelined - Seeking Alpha
Cantor Fitzgerald reiterates Overweight rating on AxoGen stock after strong Q2 - Investing.com Australia
IBD Rating Upgrades: Axogen Shows Improved Price Strength - Investor's Business Daily
Axogen Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Ichimoku Cloud Indicates Uncertainty Around Axogen Inc.Expert Verified Stock Trade Ideas Backed by Data - beatles.ru
Axogen Inc Reports Strong Q2 2025 Earnings with 18.3% Revenue Growth and BLA Approval Expected in September - AInvest
AxoGen’s Earnings Call: Strong Growth Amid Challenges - The Globe and Mail
Axogen 2025 Q2 Earnings Returns to Profitability with 130.1% Net Income Jump - AInvest
Axogen raises 2025 revenue growth target to at least 17% as BLA approval nears - MSN
AxoGen, Inc. (NASDAQ:AXGN) Q2 2025 Earnings Call Transcript - Insider Monkey
Axogen Reports Strong Q2 2025 Financial Results - The Globe and Mail
AxoGen: Q2 Earnings Snapshot - Stamford Advocate
Axogen Inc (AXGN) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements - Investing.com Canada
Axogen, Inc. Reports Strong Revenue Growth in Q2 2025 - TipRanks
Axogen (AXGN) Q2 Revenue Jumps 18% - AOL.com
AxoGen stock price target lowered to $20 by Raymond James on BLA timing - Investing.com Nigeria
Axogen (AXGN.O) Sees Sharp Intraday Move—What's Driving the Volatility? - AInvest
AxoGen reports Q2 adjusted EPS 12c, consensus 6c - TipRanks
AxoGen Q2 2025 Earnings Call Transcript - MarketBeat
Jefferies raises AxoGen stock price target to $25 on strong sales growth - Investing.com India
Jefferies raises AxoGen stock price target to $25 on strong sales growth By Investing.com - Investing.com South Africa
Axogen's Q2 2025 Earnings Call: Unpacking Contradictions in Margins, BLA Milestones, and Growth Strategies - AInvest
Transcript : Axogen, Inc., Q2 2025 Earnings Call, Aug 05, 2025 - MarketScreener
Axogen Boosts 2025 Revenue Growth Target to at Least 17% Ahead of BLA Approval. - AInvest
Axogen, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:AXGN) - Seeking Alpha
Axogen (AXGN.O) Sees Sharp Intraday Spike—What’s Driving the Volatility? - AInvest
AxoGen's Q2 Earnings Exceed Expectations with Strong Financial TurnaroundNews and Statistics - IndexBox
Axogen Stock Soars 18.25% on Strong Q2 Earnings - AInvest
AxoGen (AXGN) Beats Q2 Earnings and Revenue Estimates - Yahoo Finance
AxoGen Q2 revenue up 18.3%, beats estimates - MarketScreener
Axogen Inc earnings beat by $0.06, revenue topped estimates - Investing.com Australia
Axogen's Q2 2025 Financial Outlook and Strategic Position in the Peripheral Nerve Repair Market - AInvest
Axogen, Inc. Reports Second Quarter 2025 Financial Results - The Manila Times
AxoGen Q2 2025 Earnings Preview - MSN
Should I hold or sell Axogen Inc. stock in 2025Dynamic portfolio growth - Jammu Links News
Is it the right time to buy Axogen Inc. stockBreakthrough stock performance - Jammu Links News
Is Axogen Inc. a good long term investmentCapitalize on emerging investment opportunities - Jammu Links News
Axogen Inc Stock (AXGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.74%
0.24%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):